Her Husband Was Diagnosed With ALS, And She Knew Cutting-Edge Treatments Would Extend His Life. Now, Her Company Helps Others Get Care.
Sandra Abrevaya and her husband Brian Wallach started Synpaticure to help patients with neurodegenerative diseases access ...
STAT1d
Fueled by a ‘fall off your chair’ discovery and $101 million, Trace launches to take on ALS
A surprise finding by two independent research teams and a venture capital mega-round have birthed a biotech looking to treat ...
FierceBiotech1d
Third Rock-backed Trace uses $101M series A to go after same ALS target as Lilly
Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.
Medical Xpress on MSN12d
Study identifies 51 amyotrophic lateral sclerosis-associated mutations that could help diagnose the disease
Using sequencing techniques, researchers associated 51 mutations in mitochondrial DNA with amyotrophic lateral sclerosis (ALS ...
Natasha Alexenko, Who Exposed Backlog of Rape Cases, Dies at 51
Ten years after her sexual assault, she discovered that the evidence in her rape kit hadn’t been tested — and neither had ...
Business Wire1d
Trace Neuroscience Launches With $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases
Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...
Key pathway leading to neurodegeneration in early stages of ALS identified
Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...
Taiwan News8d
Amyotrophic Lateral Sclerosis (ALS) Market Outlook, Size, Trends, and Growth Opportunities by Type, Treatment, End User, and Region, 2024-2032
Report Ocean, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Amayotrophic Lateral Sclerosis (ALS) Market size by value at USD 902 million in 2023.
Business Insider8h
Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights
In October, Clene presented the design for RESTORE-ALS, its potentially confirmatory international Phase 3 clinical trial of CNMAu8 30 mg, at the 2024 Annual Northeast Amyotrophic Lateral Sclerosis ...
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage ...
EurekAlert!13d
Identified 51 amyotrophic lateral sclerosis-associated mutations that could help diagnose the disease
Using sequencing techniques, researchers associated 51 mutations in mitochondrial DNA with amyotrophic lateral sclerosis (ALS), an incurable degenerative neurological disorder that leads to muscle ...